(1 - 12 from 16
)
David Risinger | Benzinga
www.benzinga.com
In a report issued Tuesday, Morgan Stanley analyst David Risinger and his team reiterated an Overweight rating on Bristol-Myers Squibb Co (NYSE: BMY) The experts ...
Merck, Pfizer to Benefit From Pharma Surge: MS - Investopediawww.investopedia.com › News › Markets News
www.investopedia.com
Inc. (MRK) and Pfizer Inc. (PFE) according to Morgan Stanley analyst David Risinger. In a research note covered by Barron's, the Wall Street ...
Pfizer takes J&J to court as analysts shake up pharma ratings...
thefly.com
Pfizer takes J&J to court as analysts shake up pharma ratings. Morgan Stanley analyst David Risinger upgraded Pfizer (PFE) this morning to Overweight, a Buy-equivalent rating, as he believes investors underappreciate the global prospects for breast cancer drug Ibrance. Meanwhile, his peer at Goldman ...
sorted by relevance / date